Wedbush Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $42
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $42.
Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $42.